Tian Zhang, MD, MHS, UT Southwestern Medical Center

Articles

Dr Zhang on Topics of Ongoing Debate Within Prostate Cancer

March 12th 2024

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Dr Zhang on the Implications of Findings From the KEYNOTE-564 Trial in RCC

February 14th 2024

Tian Zhang, MD, MHS, discusses the implications of subgroup analyses from the KEYNOTE-564 trial in patients with renal cell carcinoma.

Dr Zhang on the Background of a KEYNOTE-564 Subgroup Analysis in RCC

February 7th 2024

Tian Zhang, MD, MHS, discusses using the adjuvant KEYNOTE-564 regimen to treat high-risk patients with renal cell carcinoma.

Dr Zhang on the Evolution of the Use of Belzutifan in RCC

November 22nd 2023

Tian Zhang, MD, MHS, discusses the evolution of the use of belzutifan in renal cell carcinoma, highlighting which key oncologists have been involved in this research.

Dr. Zhang on the Selection of Immunotherapy-Based Regimens in Metastatic RCC

September 27th 2023

Tian Zhang, MD, MHS, discusses the selection of first-line immunotherapy-based treatments for patients with metastatic renal cell carcinoma.

Dr Zhang on the Use of Radiation Therapy for Oligometastatic RCC

September 22nd 2023

Tian Zhang, MD, MHS, discusses the use of radiation therapy for patients with oligometastatic renal cell carcinoma.

Dr Zhang on the Potential Use of RNA Sequencing to Improve Treatment Selection in Advanced RCC

July 18th 2023

Tian Zhang, MD, MHS, discusses whether the use of RNA sequencing to identify biologic cluster assignment could improve first-line treatment selection in metastatic renal cell carcinoma.

IO Therapy in mCRPC and Clinical Pearls

May 24th 2023

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

Practical Application of PARP Inhibitors in Metastatic CRPC

May 24th 2023

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Advent of PARP Inhibitors

May 17th 2023

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm

May 17th 2023

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer

May 10th 2023

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

Educating Patients on Treatment Options in Metastatic HSPC

May 10th 2023

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1

May 3rd 2023

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.

Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES

May 3rd 2023

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE

April 26th 2023

A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.

mHSPC: Use of Triplet Therapy

April 26th 2023

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

April 19th 2023

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer

April 19th 2023

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

Optimizing Care for Patients With Non-metastatic CRPC

April 12th 2023

Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.